[1] 中华医学会肝病学分会, 中华医学会感染病学分会. 丙型肝炎防治指南(2015年更新版). 中华实验和临床感染病杂志(电子版),2015,9:590-607.
[2] Polaris Observatory HCV Collaborators.Global prevalence and genotype distribution of hepatitis C virus infection in 2015:a modelling studyLancet Gastroenterol Hepatol, 2017, 2:161-176.
[3] Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med,2002,347:975-982.
[4] European Association for the Study of the Liver. EASL recommendations on treatment of hepatitis C 2015. J Hepatol,2015,63:199-236.
[5] Foster GR, Irving WL, Cheung MC, et al. Impact of directacting antiviral therapy in patients with chronic hepatitis C and decompensated cirrhosis. J Hepatol, 2016, 64:1224-1231.
[6] Afdhal N, Reddy KR, Nelson DR, et al. Ledipasvir and sofosbuvir for previously treated HCV genotype 1 infection . N Engl J Med,2014,370:1483-1493.
[7] Ferenci P, Bernstein D, Lalezari J, et al. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med,2014,370:1983-1992.
[8] Kumada H, Suzuki Y, Ikeda K, el al. Daclatasvir plus asunaprevir for chronic HCV genotype lb infection. Hepatology,2014,59:2083-2091.
[9] Lawitz E, Mangia A, Wyles D, et al. Sofosbuvir for previously untreated chronic hepatitis C infection. N Engl J Med,2013,368:1878-1887.
[10] Lawitz E, Sulkowski MS, Ghalib R, et al. Simeprevir plus sofosbuvir,with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomized study. Lancet,2014,384:1756-1765.
[11] Mangia A, Arleo A, Copetti M, et al. The combination of daclatasvir and sofosbuvir for curing genotype 2 patients who cannot tolerate ribavirin.Liver Int,2016,36:971-976.
[12] Wyles DL, Poordad F, Wang S,et al. SURVEYOR-II,Part 3:Efficacy and safety of ABT-493/ABT-530 in patients with hepatitis C virus genotype 3 infection with prior treatment experience and/or cirrhosis.Hepatology,2016,64 Suppl 1:62A.
[13] Yeh ML, Huang CF, Hsieh MH, et al. Reactivation of hepatitis B in patients ofchronic hepatitis C with hepatitis B virus infection treated with direct-acting antivirals. J Gastroenterol Hepatol,2017,32:1754-1762.
[14] Wang C, Ji D, Chen J, et al. Hepatitis due to reactivation of hepatitis B virus in endemic areas among patients with hepatitis C treated with direct-acting antiviral agents.Clin Gastroenterol Hepatol,2017,15:132-136.
[15] Chen G, Ji D, Wang Y, et al. Non-invasive assessment of liver fibrosis and cirrhosis regression in chronic hepatitis C patients treated with pan-oral direct-acting antivirals. Hepatol Int, 2017, 11:1081-1082.
[16] Maan R, Van Tilborg M, Deterding K, et al. Safety and effectiveness of direct-acting antiviral agents for treatment of patients with chronic hepatitis C virus infection and cirrhosis. Clin Gastroenterol Hepatol,2016,14:1821-1830. |
